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Radioactive iodine (RAI) therapy is an eﬀective treatment option for Graves’ disease. However, predicting treatment failures after
RAI therapy remains controversial. The objective of this study was to investigate the factors associated with the success rate of RAI
therapy for treatment of Graves’ hyperthyroidism. Thyroid functional outcome, pre-RAI ultrasonographic features, and clinical
parameters were evaluated retrospectively in 98 patients followed up for at least 12 months after RAI (mean RAI dose was 11.7
± 1.8mCi). Hypothyroidism was achieved in 59 patients (60.2%), and euthyroidism in 16 patients (16.3%), while 23 patients
(23.5%) remained hyperthyroid. Age, sex, body mass index, pre-RAI thyroid function, or thyroid-stimulating immunoglobulin
levels were not associated with treatment outcome. Length of thyroid isthmus (p = 0 028) and 2- to 24-hour iodine uptake ratios
(p = 0 002) were signiﬁcantly associated with treatment failure, which was deﬁned as a persistent hyperthyroid status after RAI
therapy. Patients with a longer isthmus had a higher risk of remaining hyperthyroid, with a threshold for isthmus length of
5.2mm, with a sensitivity of 69.6% and speciﬁcity of 70.3% for treatment success. Measuring the length of the thyroid isthmus
can be a simple and useful way to predict RAI treatment outcome.
1. Introduction
Graves’ disease is an autoimmune thyroid disease caused by
the binding of stimulating antibodies against TSH receptors
(TRAbs) to TSH receptors on thyroid cells. This binding
stimulates follicular hypertrophy and hyperplasia, causing
thyroid enlargement as well as increased thyroid hormone
production [1]. Graves’ disease accounts for 60%–80% of
patients with hyperthyroidism, depending on regional fac-
tors, especially iodine intake [2]. It occurs more commonly
in women than in men [3]. Untreated hyperthyroidism can
lead to osteoporosis and cardiovascular complications such
as atrial ﬁbrillation and heart failure, and severe hyperthy-
roidism or thyroid storm is associated with a mortality rate
of 20–50% [4]. To date, the three main treatment options
for Graves’ disease are antithyroid drugs, thyroidectomy,
and radioactive iodine (RAI) therapy. Although the eﬃcacies
are similar among all three treatments, usually, antithyroid
drugs are associated with the higher recurrence rate of the
disease, compared to other therapeutic modalities. [5].
RAI therapy has been used since the 1940s and is the
most preferred treatment in the United States [6]. It is also
eﬀective for recurrent Graves’ disease, but the appropriate
dose of 131I is often based on empirical content, and predic-
tive factors of therapeutic eﬀects have not yet been fully
elucidated [7]. Some studies attempting to calculate the
appropriate 131I dose based on thyroid size and 24-hour
iodine uptake have reported increased eﬃcacy over ﬁxed
dose [8]. However, other studies have shown that administra-
tion of a ﬁxed dose of 131I is eﬀective, as it simpliﬁes
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procedures, reduces costs, and makes procedures more eﬃ-
cient [9, 10]. It is also important to predict the success of
treatment and improvement in thyroid function after RAI
therapy. Even though some factors such as age, sex, size of
thyroid gland, degree of hyperthyroidism before treatment,
and rate of iodine uptake by the thyroid gland have been
suggested as predictors of successful RAI treatment, it
continues to remain controversial [11, 12].
Thyroid gland volume, which is known to be the most
important factor in determining the dose and predicting the
success of treatment, is calculated mainly using ultrasonogra-
phy, and this method is known to be relatively accurate [13].
However, as Graves’ disease is characterized by thyroid
enlargement, thyroid gland volume can be cumbersome to
measure with a conventional probe and may be less accurate.
Because the length of the thyroid isthmus correlates with the
volume of the thyroid gland [14] and is easy to measure, it
can be used as an indicator before RAI treatment. The pur-
pose of this study was to analyze the associated indicators
and usefulness of thyroid isthmus length as a predictor of
RAI therapy in Graves’ disease.
2. Materials and Methods
2.1. Study Populations. Patients treated with RAI for Graves’
disease at Severance Hospital from January 2010 to Decem-
ber 2013 were followed up for more than 12 months, and
we were able to retrospectively evaluate the pretreatment thy-
roid volume in 98 patients by using cervical ultrasonography.
Patients were treated with a dose of RAI determined
semiquantitatively based on thyroid gland volume and the
24-hour RAI uptake rate on 131I scans. Patients who were
receiving antithyroid drugs had to stop medication one week
before the RAI therapy.
Treatment success was assessed using thyroid function
tests in these patients for at least twelve months after treat-
ment. RAI treatment outcomes were categorized into three
groups, hypothyroid, euthyroid, and hyperthyroid, according
to thyroid function test results at twelve months after treat-
ment. A hypothyroid or the euthyroid status was deﬁned as
RAI therapy success, whereas persistent hyperthyroidism
was deﬁned as treatment failure. The association between
RAI treatment failure and various clinical parameters includ-
ing age, sex, height, weight, body mass index (BMI), thyroid
gland volume, and isthmus length on ultrasonographic
images, thyroid function and thyroid autoantibody levels
before treatment, dose of RAI, RAI uptake rate, and serum
selenium and 25-hydroxycholecalciferol levels was analyzed.
This study was approved by the Yonsei University College of
Medicine Institutional Review Board (4-2017-0134).
2.2. Thyroid Function and Antithyroid Antibody Test. Serum
concentrations of TSH (normal range, 0.35–4.94 IU/mL),
free T4 (normal range, 0.70–1.48ng/dL), and T3 (normal
range, 0.58–1.59 ng/mL) for thyroid function evaluation were
measured by microparticle chemiluminescence immunoas-
say (Abbott Ireland Diagnostics Division, Longford, Ireland).
TRAb levels were measured by two diﬀerent methods: M22-
TRAb (TRAb) was measured by a third-generation TBII
electrochemiluminescence immunoassay (Elecsys/Cobas;
Roche Diagnostics, Mannheim, Germany) and Mc4-TSAb
(thyroid-stimulating immunoglobulin, TSI) was measured
by the Thyretain™ TSI reporter BioAssay (Diagnostic
Hybrids Inc., Athens, OH, USA). The antibody test was
deﬁned as positive when TRAb levels were higher than
1.75 IU/L and Mc4-TSAb was higher than the standard value
of the sample ratio of 140%. Concentrations of thyroglobulin
antibody (normal range, 0–130.6 IU/mL) and thyroperoxi-
dase antibody (normal range, 0–13.7 IU/mL) as a thyroid
autoantibody were measured by electrochemiluminescence
immunoassay (Roche Diagnostics, Mannheim, Germany).
2.3. Thyroid Volume Measurement. Gray-scale ultrasonogra-
phy evaluation of the thyroid gland was performed with a 5
to 12MHz linear transducer (iU22; Philips Medical Systems,
Bothell, WA, USA) or a 6 to 13MHz linear transducer
(EUB-7500; Hitachi Medical, Tokyo, Japan). For imaging
of the thyroid gland, the patients were instructed to take
a supine position with a cushion under the shoulder and
neck hyperextended.
The ultrasonographic procedure for the total volumemea-
surement was performed as previously described by Ueda
[15]. In other words, each lobe of the thyroid gland was
assumed to be a prolate spheroid. We then measured the
height (D1), width (D2), and depth (D3) of each lobe. The vol-
ume of each lobe was calculated using a standard geometric
formula: volume of a prolate ellipsoid =D1×D2×D3× 0.523.
The volume of the whole thyroid gland was estimated as the
sum of the volume of each lobe.
Table 1: Baseline clinical characteristics of patients with Graves’
disease.
Characteristic Total patients (n = 98)
Age, years 44.1± 14.0
Sex (female, %) 67 (68.4%)
Follow-up duration, months 33.1± 14.0
BMI, kg/m2 23.4± 3.2
Isthmus, mm 5.4± 3.2
Thyroid volume, cm3 32.3± 21.0
Pre-RAI T3, ng/mL 1.85± 0.97
Pre-RAI free T4, ng/mL 2.05± 1.22
Undetectable TSH (n, %) 76 (77.6%)
Pre-RAI TRAb, IU/L 13.45± 14.21
Pre-RAI TSI, % 318.5± 208.7
RAI dose, mCi 11.7± 1.8
2-hour uptake, % 44.3± 22.5
24-hour uptake, % 66.0± 21.5
2-hour/24-hour ratio 0.65± 0.24
Serum selenium, μg/L 118.2± 17.1
Serum 25(OH)D, ng/dL 19.0± 9.1
Data are presented as mean ± SD or number (%). BMI: body mass index;
RAI: radioactive iodine; TRAb: TSH receptor antibody; TSI: thyroid-
stimulating immunoglobulin; 25(OH)D: 25-hydroxycholecalciferol.
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2.4. Deﬁnition of Treatment Eﬀect. Hypothyroid patients had
a persistently low free T4 concentration and an elevated TSH
concentration within six months after therapy and had been
on levothyroxine therapy to normalize TSH concentrations.
Euthyroidism was deﬁned as serum T4 and TSH concentra-
tions within the normal range without levothyroxine replace-
ment at six months. Hyperthyroidism was deﬁned as free T4
that remained elevated and suppressed TSH or a continued
requirement for antithyroid medication.
2.5. Statistical Analysis. The variables of each group were
compared based on the results of the ﬁrst radioisotope treat-
ment. Continuous variables are reported as mean± standard
deviation and analyzed by one-way ANOVA. For compari-
son and analysis of categorical variables, a χ2 test was used.
The results and the factors aﬀecting these results were
analyzed by multivariate logistic regression analysis. Receiver
operating characteristic (ROC) curves were used to deter-
mine the threshold of thyroid isthmus length or thyroid
volume to predict the success of radioisotope therapy. Statis-
tical signiﬁcance was deﬁned as a p value less than 0.05.
Statistical analysis was performed using SPSS version 23
(IBM Corp., Armonk, NY, USA).
3. Results
3.1. Clinical Characteristics of Patients and Analysis of
Clinical Factors according to RAI Treatment Results. There
were 98 patients (31 men, 67 women) with Graves’ disease
with a mean age of 44.1± 14.0 years. The mean follow-up
duration was 33.1± 14.0 months. The mean volume of the
thyroid gland measured by ultrasonography was 32.3
± 21.0 cm3, and the mean length of the thyroid isthmus was
5.4± 3.2mm. In the thyroid function test before RAI treat-
ment, T3 was elevated to 1.85± 0.97 ng/mL (normal range,
0.58–1.59 ng/mL), free T4 was elevated to 2.05± 1.22ng/mL
(normal range, 0.70–1.48 ng/dL), and TSH was suppressed
to below the measurement range in approximately 77.6% of
the patients. TRAb positivity before RAI treatment was
found in approximately 88.8% of the patients, and the mean
TRAb level was 13.45± 14.21 IU/L (normal range, below
1.75 IU/L). The mean dose of RAI administered was 11.7
± 1.8mCi (Table 1).
Based on the results of the ﬁrst RAI treatment, the
patients were divided into a hypothyroid group (59 patients,
60.2%), normal function group (16 patients, 16.3%), and
persistent hyperthyroid group (23 patients, 23.5%). There
was no diﬀerence in mean age, sex ratio, follow-up period,
height, weight, or BMI among the three groups. The mean
thyroid volume was 53.5± 27.1 cm3 in the hyperthyroid
group, which was signiﬁcantly larger than that in the euthy-
roid group (29.2± 10.6 cm3) (p = 0 001) and in the hypothy-
roid group (24.7± 13.7 cm3) (p < 0 001), and the mean
length of the thyroid isthmus was the longest (8.0± 4.2mm)
in the hyperthyroid group (p < 0 001). The mean TRAb level
was the highest (20.25± 20.08 IU/L) in the hyperthyroidism
Table 2: Comparison between patients of diﬀerent outcome groups after the ﬁrst RAI treatment.
Hypothyroid Euthyroid Hyperthyroid p
Number of patients 59 (60.2%) 16 (16.3%) 23 (23.5%)
Age, years 43.5± 13.5 50.1± 17.0 41.4± 12.4 0.149
Sex (male : female) 22 : 37 3 : 13 6 : 17 0.297
Follow-up duration, months 34.3± 12.7 34.5± 13.8 29.2± 17.0 0.314
Height, cm 162.9± 7.4 159.1± 8.0 163.3± 7.9 0.236
Weight, kg 61.6± 11.4 60.0± 8.7 61.6± 13.5 0.827
BMI, kg/m2 23.3± 3.1 23.7± 2.7 23.3± 3.9 0.931
Isthmus, mm 4.5± 2.5 5.2± 1.6 8.0± 4.2 <0.001
Thyroid volume, cm3 24.7± 13.7 29.2± 10.6 53.5± 27.1 <0.001
Pre-RAI T3, ng/mL 1.98± 1.15 1.52± 0.39 1.75± 0.52 0.241
Pre-RAI free T4, ng/mL 1.95± 1.14 1.84± 1.59 2.47± 1.09 0.165
Pre-RAI TRAb, IU/L 12.24± 11.77 7.98± 7.82 20.25± 20.08 0.030
Pre-RAI TSI, % 305.2± 213.8 331.9± 184.2 343.6± 220.0 0.793
Pre-RAI TPO Ab, IU/mL 267.9± 241.8 233.5± 264.1 356.8± 226.1 0.226
Pre-RAI Tg Ab, IU/mL 786.1± 1310.8 337.9± 690.2 409.1± 840.4 0.247
RAI dose, mCi 11.5± 1.5 12.8± 2.8 11.3± 1.5 0.191
2-hour uptake, % 41.8± 21.1 38.2± 21.3 54.8± 24.3 0.030
24-hour uptake, % 66.1± 20.8 61.1± 22.7 69.1± 22.7 0.524
2-hour/24-hour ratio 0.60± 0.21 0.60± 0.23 0.80± 0.26 0.002
Serum selenium, μg/L 121.0± 17.5 108.7± 14.9 117.4± 15.9 0.101
Serum 25(OH)D, ng/mL 18.0± 9.2 22.8± 10.5 19.1± 7.9 0.471
Data are presented as mean ± SD or number (%). One-way ANOVA and χ2 tests were performed. BMI: body mass index; RAI: radioactive iodine;
TRAb: TSH receptor antibody; TSI: thyroid-stimulating immunoglobulin; TPO Ab: thyroperoxidase antibody; Tg Ab: thyroglobulin antibody;
25(OH)D: 25-hydroxycholecalciferol.
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group, which was signiﬁcantly higher than that in the euthy-
roid group (7.98± 7.82 IU/L) (p = 0 037). However, TSI
values did not diﬀer among the three groups (p = 0 793),
and there was no signiﬁcant diﬀerence in other thyroid
autoantibodies. There was no diﬀerence in the adminis-
tered dose of RAI among the three groups (p = 0 191). In
the 131I scan, the 2-hour intake rate was highest in the
hyperthyroid group, followed by the hypothyroid group
and then the euthyroid group, and the diﬀerence was
statistically signiﬁcant (p = 0 030). However, with regard
to the 24-hour intake rate, there was no signiﬁcant diﬀer-
ence among the three groups. The 2- to 24-hour 131I
uptake ratio was signiﬁcantly higher in the persistent
hyperthyroid group (p = 0 002) (Table 2).
3.2. Correlation between Thyroid Isthmus Length and Success
of RAI Treatment. As shown above, the mean length of the
thyroid isthmus was longer in the hyperthyroidism group
(8.0± 4.2mm) than in the other groups (p < 0 001). The
distribution of isthmus length according to treatment
results after RAI therapy can be seen in Figure 1. Thus,
the longer the isthmus length, the more likely that
hyperthyroidism persisted. This tendency was more pro-
nounced when the treatment success rate was compared
between groups divided according to isthmus length of
2mm. When the isthmus length is less than 2mm, the
treatment success rate is close to 100%, but as the isth-
mus length becomes longer, the success rate gradually
decreases and is about 41% when the isthmus length is
8mm or more (Figure 2). There was also a signiﬁcant
positive correlation between isthmus length and treatment
failure (p < 0 001, r = 0 453).
3.3. Threshold Values of Isthmus Length Related to Successful
RAI Treatment. To determine the threshold values of isth-
mus length related to successful RAI in patients with
Graves’ disease, an ROC curve was used. For a thyroid
volume of 35 cm3, the sensitivity was 82.6% and the
speciﬁcity was 81.1% (AUC, 0.852; p < 0 001). For an isth-
mus length of 5.2mm, the sensitivity was 69.6% and the
speciﬁcity was 70.3% (AUC, 0.746; p < 0 001). We found
a failure rate of 41.7% among patients with thyroid
isthmus length> 5.2mm and 13.1% in those with thyroid
isthmus length≤ 5.2mm (p = 0 001). The overall treatment
success rate was 76.5% (Figure 3).
3.4. Factors Associated with Treatment Failure after RAI
Treatment. Multivariate logistic regression analysis was used
to identify variables related to RAI treatment failure. An
isthmus length> 5.2mm (OR, 4.50; 95% CI, 1.18–17.24;
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Figure 1: Distribution of isthmus length based on treatment results after radioactive iodine therapy.
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Figure 2: Success rates of radioactive iodine therapy for various
isthmus length subgroups in patients with Graves’ disease. Data
are presented as number of patients with treatment success/total
patients.
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p = 0 028) and a 2- to 24-hour iodine uptake rate more
than 0.8 (OR, 8.10; 95% CI, 2.10–31.23; p = 0 002) were
signiﬁcantly associated with treatment failure deﬁned as
a persistent hyperthyroid status after RAI therapy. There
were no signiﬁcant diﬀerences in age, sex, administered
131I dose, or TRAb level (Table 3). When thyroid volume
was analyzed in the same model, instead of isthmus
length, thyroid volume> 35 cm3 (OR, 11.89; 95% CI,
2.63–53.68; p = 0 001) was signiﬁcantly associated with
persistent hyperthyroid status after RAI therapy.
4. Discussion
Our study has shown that an isthmus length of 5.2mm or
more and a 2- to 24-hour iodine uptake rate of 0.8 or
more were independent predictors of treatment failure
after RAI treatment. The likelihood of a failed ﬁrst RAI
treatment was higher in patients with Graves’ disease if
the isthmus length was longer. Using an ROC curve, we
determined the threshold values of isthmus length related
to successful RAI in patients with Graves’ disease. On
the contrary, the mean level of TRAb was higher in the
hyperthyroidism group in univariate analysis, but it was
not signiﬁcant in multivariate analysis.
RAI treatment has been used to treat Graves’ disease for
the past 60 years and, during that time, has been proven to
be both safe and eﬀective, as a primary treatment or when
antithyroid drugs are not able to resolve thyrotoxicosis. In
the United States, RAI treatment is the most preferred, while
in Japan, Korea, and Europe, antithyroid drugs are the pre-
ferred treatment [6]. Most patients become euthyroid state,
and clinical signs improve within 4–8 weeks after RAI treat-
ment. Hypothyroidism may appear from the fourth week
onward, but most often occurs within 2–6 months. The per-
sistence of hyperthyroidism at six months after RAI treat-
ment heralds the probable requirement of an additional
dose of RAI treatment. Therefore, identifying patients with
a high possibility of RAI treatment failure plays an important
role in precise follow-up and additional treatment decisions.
Thyroid ultrasonography is a useful tool for detecting
Graves’ disease [16]. It is well known that the larger the thy-
roid volume, the higher is the probability for RAI treatment
failure [17, 18]. However, to obtain the thyroid volume, the
height, the width, and the depth of thyroid must be
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Figure 3: Receiver operating characteristic curve used to determine threshold values of isthmus length related to successful radioactive iodine
therapy in patients with Graves’ disease. (a) For a volume of 35 cm3, sensitivity was 82.6%, and speciﬁcity was 81.1% (AUC, 0.852; p < 0 001).
(b) For an isthmus length of 5.2mm, sensitivity was 69.6%, and speciﬁcity was 70.3% (AUC, 0.746, p < 0 001).
Table 3: Multivariate logistic regression analysis of factors
associated with persistent hyperthyroid status after radioactive
iodine therapy.
Factor OR (95% CI) p
Age, years 0.99 (0.95–1.05) 0.841
Sex (female) 1.33 (0.30–5.85) 0.711
BMI, kg/m2 0.95 (0.77–1.16) 0.592
Isthmus length, mm
≤5.2 Reference
>5.2 4.50 (1.18–17.24) 0.028
2-hour/24-hour 131I uptake ratio
≤0.8 Reference
>0.8 8.10 (2.10–31.23) 0.002
Administered 131I dose, mCi 0.85 (0.58–1.25) 0.406
TSH receptor antibody, IU/L 1.01 (0.96–1.06) 0.755
BMI: body mass index.
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measured, and complex formulas need to be used to calculate
the thyroid volume. Furthermore, it may be diﬃcult to obtain
the thyroid volume in patients whose thyroid is enlarged by
goiter. On the contrary, the thyroid isthmus length is easy to
measure and correlates with thyroid volume [14]. Therefore,
if the relationship between isthmus length and RAI treatment
outcome was conﬁrmed, thyroid isthmus length could be a
useful clinical parameter in the decision process of RAI treat-
ment. In our study, using the ROC curve, we found that the
cutoﬀ value of the isthmus length that increases the probabil-
ity of treatment failure was 5.2mm. Therefore, physicians
considering RAI therapy for patients with Graves’ disease
need to carefully measure the length of the isthmus using
ultrasonography to predict the therapeutic outcome.
A higher 2- to 24-hour 131I uptake ratio in the thyroid
gland could reﬂect a faster iodine turnover in thyroid cells,
thus shortening the residual time of therapeutic 131I in the
thyroid gland and therefore contributing to treatment failure
[19]. The time for performing a thyroid scan to measure the
iodine uptake ratio varies slightly across studies [18–20]. We
used the 2- to 24-hour 131I uptake ratio as an index to pre-
dict rapid 131I turnover, as this is known to be an important
factor in predicting the therapeutic outcome. According to
multivariate logistic regression, when the 2- to 24-hour 131I
uptake rate was more than 0.8, the probability of treatment
failure was statistically signiﬁcantly higher than when it
was 0.8 or less.
The inverse relationship of high thyroid volumes and
RAI treatment failure was ﬁrst studied by Goolden and
Fraser [21], but to the best of our knowledge, there were
no studies on the relationship between RAI treatment
and thyroid isthmus length. As it is easy to determine isth-
mus length, it is expected to be highly useful in clinical prac-
tice. Additionally, if used together with the 2- to 24-hour 131I
uptake ratio, a more accurate selection of candidate patients
with Graves’ disease for whom RAI treatment is more eﬀec-
tive and beneﬁcial can be possible.
This study has some limitations that should be addressed.
First, the patients involved in this study were from a center in
South Korea, where antithyroid drugs are the most com-
monly used primary treatment for Graves’ disease [22].
Therefore, there may have been a selection bias, and the
enrolled subjects in this study might be somewhat refractory
to the usual antithyroid drug treatment. Further studies are
required to conﬁrm these results and to generalize the clinical
usefulness of thyroid isthmus length in treatment-naive
patients. Second, as a retrospective study, this study was lim-
ited in controlling all the clinical parameters confounding
RAI treatment eﬃcacy. More prospective controlled studies
carried out in larger patient populations in multiple centers
are needed. Third, in the measurement of thyroid volume
and isthmus length using ultrasonography, minor errors
might occur depending on the operator even though objec-
tive criteria were used.
5. Conclusion
The results from our study are consistent with the results
from previous studies showing that increased thyroid volume
and a higher 131I uptake ratio increased the probability of
RAI treatment failure [17, 18]. In addition, we found that
the longer the isthmus length, the higher was the probability
of RAI treatment failure, with a cutoﬀ value of 5.2mm. Phy-
sicians considering RAI therapy for patients with Graves’ dis-
ease can adopt this simple and useful parameter as an
additional predictive factor of therapeutic outcome.
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